Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo
2014
Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer
2008
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
2009
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/ protein and vascular endothelial growth factor
2002
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Stroke rehabilitation
2011 Standout
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
The extracellular domain of Her2 in serum as a biomarker of breast cancer
2018
The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
2002
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
2011 Standout
Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations
2006
The relationship between prognostic and predictive factors in the management of breast cancer
1998
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
2000
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma
2003 StandoutNobel
Circuit class therapy for improving mobility after stroke
2017
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Procollagen I COOH-terminal fragment induces VEGF-A and CXCR4 expression in breast carcinoma cells
2008
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
2012
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
2005
Estrogen receptors and human disease
2006 Standout
Breast cancer
2016 Standout
Cellular senescence: when bad things happen to good cells
2007 Standout
Role of Gemcitabine in Breast Cancer Management: An Update
2006
Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group
2006
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Lumpectomy Plus Tamoxifen or Anastrozole With or Without Whole Breast Irradiation in Women With Favorable Early Breast Cancer
2007
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
EGF–ERBB signalling: towards the systems level
2006 Standout
Enzymatic rationale and preclinical support for a potent protein kinase Cβ inhibitor in cancer therapy
1999
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
2002 Standout
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen
2006
Estrogen Receptor Beta (ESR2) Polymorphisms in Familial and Sporadic Breast Cancer
2005
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Bone health in cancer patients: ESMO Clinical Practice Guidelines
2014
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
2010
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
2012
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Role of bisphosphonates in postmenopausal women with breast cancer
2013
p53 in health and disease
2007 Standout
Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.
1998
Emerging Biological Principles of Metastasis
2017 Standout
Collective cell migration in morphogenesis, regeneration and cancer
2009 Standout
Risk of early recurrence among postmenopausal women with estrogen receptor‐positive early breast cancer treated with adjuvant tamoxifen
2008
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
p53 mutation heterogeneity in cancer
2005
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer
2000
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Analysis of Cytochrome P450 CYP119 Ligand-dependent Conformational Dynamics by Two-dimensional NMR and X-ray Crystallography
2015
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)
2009
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
2007
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature
2011
Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary Results
2002
Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer
2006
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Stromal MCP‐1 in mammary tumors induces tumor‐associated macrophage infiltration and contributes to tumor progression
2009
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Effects of Bone-Targeted Agents on Cancer Progression and Mortality
2012
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Tumor Angiogenesis
2008 Standout
First international consensus guidelines for breast cancer in young women (BCY1)
2014
Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients
2000
Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression
2006
Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer
2005
NF-κB: linking inflammation and immunity to cancer development and progression
2005 Standout
Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer
2000
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
2002 StandoutNobel
Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression
2003
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
2012 StandoutNobel
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
2001 StandoutNobel
Breast Cancer Treatment
2019 Standout
Impact of pretreatment thrombocytosis on survival in primary breast cancer
2003
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
2003
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
2009
Progress and prospects of early detection in lung cancer
2017
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
2006
Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.
2001
Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
2003
Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188)
2005
Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**
2021 StandoutNobel
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade
2007
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Structural Adaptability Facilitates Histidine Heme Ligation in a Cytochrome P450
2015 StandoutNobel
Works of Michael Seifert being referenced
Tissue Expression and Serum Levels of HER-2/neu in Patients with Breast Cancer
1997
Significant Increase in Breast Conservation in 16 Years of Trials Conducted by the Austrian Breast & Colorectal Cancer Study Group
2003
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
2005
MMP-2 and MMP-9 Expression in Breast Cancer-Derived Human Fibroblasts is Differentially Regulated by Stromal-Epithelial Interactions
2002
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
1999
Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival
1997
Evidence that Tamoxifen Preserves Bone Density in Late Postmenopausal Women with Breast Cancer
1998
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
2011
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
2008
Physical fitness training in Subacute Stroke (PHYS-STROKE) - study protocol for a randomised controlled trial
2014
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
2013
Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer
2000
Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype.
2003
Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6
2003
Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines
2002
Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5
2002